Nonalcoholic fatty liver disease (NAFLD),Nonalcoholic steatohepatitis (NASH),Type 2 diabetes,Central obesity,Cardiometabolic risks,Insulin resistance,High plasma aminotransferase levels (AST/ALT >30 units/L for >6 months),Cirrhosis,Hepatocellular carcinoma,Decompensated cirrhosis